The government of São Paulo announces on Monday (19) that the vaccine Coronavac, developed by the Butantan Institute in partnership with the Chinese pharmaceutical company Sinovac, also proved to be safe in tests with 9,000 Brazilian volunteers, reaffirming the results of previous research with 50,000 Chinese participants. The information is from the newspaper The State of São Paulo.
The effectiveness data, however, should only be released between November and December, which may delay the governor’s forecast João Doria (PSDB) to start immunization still this year.
According to Dimas Covas, director of Butantã, the tests with the 13 thousand volunteers have not been finalized and the analysis of effectiveness cannot yet be done. The researcher stated that only the first stage of the study, with 9 thousand people, was concluded this week.
Even in this group, not everyone has taken both doses yet, which should happen by the end of the month. “We already have the safety data for this stage, they are very similar to the Chinese (a study in which more than 90% of the volunteers had no adverse events). It is these data that I will detail in the second one ”, he said.
With information from Estadão.